Skip to main navigation menu Skip to main content Skip to site footer

Original article

Vol. 148 No. 0708 (2018)

Overuse of antimicrobial prophylaxis in low-risk patients undergoing transurethral resection of the prostate

  • Kathrin Bausch
  • Jan A. Roth
  • Hans-H. Seifert
  • Andreas F. Widmer
Cite this as:
Swiss Med Wkly. 2018;148:w14594



To evaluate the current antimicrobial prophylaxis practices for low-risk patients undergoing transurethral resection of the prostate (TURP) or photoselective vaporisation of the prostate (PVP) in comparison with the antimicrobial prophylaxis recommendations of the European Association of Urology (EAU), which have been shown to effectively reduce infectious complications and antimicrobial resistance rates.


In May 2017, we sent an anonymous online -survey to board-certified urologists in Germany, Austria and Switzerland, by use of the database directory of the respective urology associations. Besides demographical questions, urologists were asked about their sources of information on antimicrobial prophylaxis prescription and their prescribing patterns before, during and after surgery in patients without an indwelling catheter or significant bacteriuria undergoing TURP or PVP.


Overall, 374 of 5825 urologists responded, of whom 76% (286/374) performed TURP and 16% (60/374) PVP. For TURP and PVP, respectively: (i) 42% (119/286) and 33% (20/60) reported routine use of preoperative antimicrobial prophylaxis, which does not conform to guideline recommendations; (ii) 43% (124/286) and 52% (31/60) reported prescribing non-recommended perioperative antimicrobial prophylaxis regimens; and (iii) 60% (172/286) and 65% (39/60) routinely extended antimicrobial prophylaxis after surgery for up to one week. In summary, of the urologists who responded to the questionnaire, 74% (211/286) reported nonadherence to guidelines on antimicrobial prophylaxis for TURP.


A low adherence to guidelines for low-risk patients undergoing TURP or PVP was reported. Given these preliminary data, there is an urgent need to monitor adherence to antimicrobial prophylaxis guidelines in urology to reduce antimicrobial resistance rates.


  1. Bonkat G, Pickard R, Bartoletti R, et al. EAU Guidelines on Urological Infections. Perioperative antibacterial prophylaxis in urology. In: Complete European Association of Urology Guidelines. Edn. presented at the EAU Annual Congress London 2017. 2017. pp 35–9.
  2. Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Hermanek P, et al.; Urology Section of the Bavarian Working Group for Quality Assurance. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol. 2008;180(1):246–9. doi:.
  3. Ruszat R, Wyler S, Forster T, Reich O, Stief CG, Gasser TC, et al. Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol. 2007;51(4):1031–8, discussion 1038–41. doi:.
  4. Blaettler L, Mertz D, Frei R, Elzi L, Widmer AF, Battegay M, et al. Secular trend and risk factors for antimicrobial resistance in Escherichia coli isolates in Switzerland 1997-2007. Infection. 2009;37(6):534–9. doi:.
  5. World Health Organization. Global guidelines on the prevention of surgical site infection. Geneva: World Health Organization; 2016. Available from:
  6. Alsaywid BS, Smith GH. Antibiotic prophylaxis for transurethral urological surgeries: Systematic review. Urol Ann. 2013;5(2):61–74. doi:.
  7. Berry A, Barratt A. Prophylactic antibiotic use in transurethral prostatic resection: a meta-analysis. J Urol. 2002;167(2 Pt 1):571–7.
  8. Qiang W, Jianchen W, MacDonald R, Monga M, Wilt TJ. Antibiotic prophylaxis for transurethral prostatic resection in men with preoperative urine containing less than 100,000 bacteria per ml: a systematic review. J Urol. 2005;173(4):1175–81. doi:.
  9. Wilson JR, Puri R, Prescott S, Urwin GH. The catheterized patient undergoing transurethral resection of the prostate: a survey of the current practice of British urologists. BJU Int. 2003;92(6):589–91. doi:.
  10. Çek M, Tandoğdu Z, Naber K, Tenke P, Wagenlehner F, van Oostrum E, et al.; Global Prevalence Study of Infections in Urology Investigators. Antibiotic prophylaxis in urology departments, 2005-2010. Eur Urol. 2013;63(2):386–94. doi:.
  11. Wagenlehner F, Stöwer-Hoffmann J, Schneider-Brachert W, Naber KG, Lehn N. Influence of a prophylactic single dose of ciprofloxacin on the level of resistance of Escherichia coli to fluoroquinolones in urology. Int J Antimicrob Agents. 2000;15(3):207–11. doi:.
  12. Bonkat G, Müller G, Braissant O, Frei R, Tschudin-Suter S, Rieken M, et al. Increasing prevalence of ciprofloxacin resistance in extended-spectrum-β-lactamase-producing Escherichia coli urinary isolates. World J Urol. 2013;31(6):1427–32. doi:.
  13. Bantar C, Sartori B, Vesco E, Heft C, Saúl M, Salamone F, et al. A hospitalwide intervention program to optimize the quality of antibiotic use: impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance. Clin Infect Dis. 2003;37(2):180–6. doi:.
  14. Cai T, Verze P, Brugnolli A, Tiscione D, Luciani LG, Eccher C, et al. Adherence to European association of urology guidelines on prophylactic antibiotics: An important step in antimicrobial stewardship. Eur Urol. 2016;69(2):276–83. doi:.

Most read articles by the same author(s)